Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.71 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.64 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.64 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8120151 | 0.83 | CYP3A4 (0.70) | CYP3A4CYP11B2CYP11B1CYP17A1CYP19A1 | |
| SCHEMBL18770372 | 0.83 | CYP3A4 (1.00) | CYP3A4CYP11B2CYP11B1CYP17A1KDM1A | |
| SCHEMBL8126674 | 0.80 | CYP3A4 (0.47) | CYP3A4CYP11B2CYP11B1CYP17A1KDM1A | |
| SCHEMBL18770353 | 0.78 | CYP3A4 (1.00) | CYP3A4CYP11B2CYP11B1CYP17A1 | |
| SCHEMBL4127579 | 0.77 | CYP3A4 (0.47) | CYP3A4CYP11B2CYP11B1KDM1ARORC | |
| SCHEMBL5749365 | 0.77 | KDM1A (0.58) | CYP3A4KDM1ALMNACYP2C19 | |
| SCHEMBL31650219 | 0.77 | KDM1A (0.58) | CYP3A4KDM1ALMNACYP2C19 | |
| SCHEMBL4133169 | 0.75 | CYP3A4 (0.58) | CYP3A4CYP11B2CYP11B1CYP17A1KDM1A | |
| SCHEMBL18770312 | 0.75 | CYP3A4 (1.00) | CYP3A4CYP11B2CYP11B1CYP17A1 | |
| SCHEMBL7321561 | 0.74 | SIGMAR1 (0.51) | CYP3A4CYP11B2CYP11B1KDM1ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | CYP3A4 2377/4885CYP11B2 429/4885CYP11B1 368/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | CYP3A4 1529/4885CYP11B2 586/4885CYP11B1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.